U.S. Markets open in 1 hr 55 mins

Galena price target raised to $11 from $7 at Roth Capital

Roth Capital increased its price target on Galena after the company acquired Mills Pharmaceuticals and its development product, GALE-401. The firm believes that GALE-401 could be safer than the drug currently used to treat Essential Thrombocythemia patients, and adds that GALE-401 may be given to young patients that do not receive the current treatment. Roth keeps a Buy rating on the stock.